Abstract Number: 2230 • 2019 ACR/ARP Annual Meeting
Applicability of FRAX in Clinical Practice: 10-year Results
Background/Purpose: Applicability of FRAX in Clinical Practice. Results at 10 yearsTo evaluate the applicability of: 1) the fracture risk thresholds that we proposed in 2013…Abstract Number: 2231 • 2019 ACR/ARP Annual Meeting
Improving Compliance with Screening for Osteoporosis in Elderly Women
Background/Purpose: US Preventive Task Force (USPSTF) recommends screening for osteoporosis in women ≥ 65 years of age with dual-energy X-ray absorptiometry (DEXA) scan. There was…Abstract Number: 2232 • 2019 ACR/ARP Annual Meeting
Results of the Implementation of a Bone Health Program in Patients with Rheumatoid Arthritis to Improve the Evaluation of Osteoporosis
Background/Purpose: Osteoporosis is a generalized skeletal disorder characterized by compromised bone strength and deterioration of quality, often leading to fragility fractures (1). People with rheumatoid…Abstract Number: 2233 • 2019 ACR/ARP Annual Meeting
Hip Fracture Incidence in a Teaching Hospital: Intervention for the Prevention of Second Hip Fracture
Background/Purpose: Since March 2009, every patient who was admitted in the Orthopaedic Surgery Department for a hip fracture (HF) was evaluated during the admission period…Abstract Number: 2234 • 2019 ACR/ARP Annual Meeting
Osteoporosis Screening in a Resident-Driven Clinic of a Large Academic Hospital
Background/Purpose: Osteoporosis is associated with fragility fractures and represents a significant public health problem. The United States Preventive Services Task Forces (USPSTF) recommend dual-energy x-ray…Abstract Number: 2235 • 2019 ACR/ARP Annual Meeting
Osteoporosis Screening in African American Patients of Rheumatoid Arthritis Patients: Are We Doing Enough?
Background/Purpose: Osteoporosis is a well-known extra-articular complication in rheumatoid arthritis (RA) patients It is more common in patients with RA than in the general population,…Abstract Number: 2236 • 2019 ACR/ARP Annual Meeting
Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations
Background/Purpose: Strength training (ST) rates in people with rheumatoid arthritis (RA) are remarkably low (1-14%), reducing the potential health benefits of ST for this population…Abstract Number: 2237 • 2019 ACR/ARP Annual Meeting
Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies
Background/Purpose: Treat-to-target (T2T) strategy has become the best approach to treat several rheumatic disorders. However, most targets are only based on specialists’ opinions, which may…Abstract Number: 2238 • 2019 ACR/ARP Annual Meeting
Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach
Background/Purpose: Treatment of rheumatoid arthritis (RA) to remission optimally ensures control of symptoms, prevention of structural damage, optimization of function and quality of life. Adherence…Abstract Number: 2239 • 2019 ACR/ARP Annual Meeting
Reproductive Health Awareness and Needs: Assessment of Parents, Female Adolescents, and Young Adults with Pediatric Rheumatic Diseases
Background/Purpose: The diagnosis of a pediatric rheumatic disease comes with worries for both parents and patient; one that may be overlooked is the impact on…Abstract Number: 2240 • 2019 ACR/ARP Annual Meeting
Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis
Background/Purpose: Our hypothesis is that patients have a positive opinion regarding the newer, biologic DMARDs and a negative sentiment towards the conventional synthetic agents. We…Abstract Number: 2241 • 2019 ACR/ARP Annual Meeting
Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Background/Purpose: While juvenile myositis (JM) can negatively affect quality of life, studies of the emotional health needs of youth with JM are limited. We examined…Abstract Number: 2242 • 2019 ACR/ARP Annual Meeting
Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Background/Purpose: The FDA uses near or total clearance in cutaneous disease in inflammatory skin conditions as an endpoint in clinical trials. However, patients may experience…Abstract Number: 2243 • 2019 ACR/ARP Annual Meeting
Knowledge, Needs and Expectations Among Systemic Lupus Erythematosus: Preliminary Results from the INTEGRATE Pilot Project
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disease characterized by multi-organ involvement and a complex clinical picture, with a wide range of manifestations…Abstract Number: 2244 • 2019 ACR/ARP Annual Meeting
What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?
Background/Purpose: To describe patterns of care and physician satisfaction with prescribed treatments for osteoarthritis (OA).Methods: Data were collected from February-May 2017 using US Adelphi Disease…
- « Previous Page
- 1
- …
- 905
- 906
- 907
- 908
- 909
- …
- 2425
- Next Page »